RT Journal Article
T1 Irisin, two years later
A1 Garrido Novelle, Marta
A1 Contreras Jiménez, Cristina
A1 Romero Picó, Amparo
A1 López, Miguel
A1 Diéguez, Carlos
AB In January 2012, Boström and colleagues identified a new muscle tissue secreted peptide, which they named irisin, to highlight its role as a messenger that comes from skeletal muscle to other parts of the body. Irisin is a cleaved and secreted fragment of FNDC5 (also known as FRCP2 and PeP), a member of fibronectin type III repeat containing gene family. Major interest in this protein arose because of its great therapeutic potential in diabetes and perhaps also therapy for obesity. Here we review the most important aspects of irisin’s action and discuss its involvement in energy and metabolic homeostasis and whether the beneficial effects of exercise in these disease states could be mediated by this protein. In addition the effects of irisin at the central nervous system (CNS) are highlighted. It is concluded that although current and upcoming research on irisin is very promising it is still necessary to deepen in several aspects in order to clarify its full potential as a meaningful drug target in human disease states.
PB Wiley
SN 1687-8337
YR 2013
FD 2013
LK https://hdl.handle.net/20.500.14352/94891
UL https://hdl.handle.net/20.500.14352/94891
LA eng
NO Novelle, Marta G., et al. «Irisin, Two Years Later». International Journal of Endocrinology, vol. 2013, 2013, pp. 1-8. https://doi.org/10.1155/2013/746281.
NO The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under Grant agreement no. 281854—the ObERStress European Research Council Project(ML) and no. 245009—the Neurofast project (ML and CD), and Xunta de Galicia (ML: 10PXIB208164PR and 2012-CP070), Instituto de Salud Carlos III (ISCIII) (ML: PI12/01814), MINECO were co-funded by the FEDER Program of EU (CD:BFU2011-29102). CIBER de Fisiopatología de la Obesidad y Nutrición is an initiative of ISCIII.
NO Instituto de Salud Carlos III
NO European Commission
NO Xunta de Galicia
DS Docta Complutense
RD 9 abr 2025